Is Age-targeted full-field digital mammography screening cost-effective in emerging countries? A micro simulation model

[1]  C. Polanczyk,et al.  Is full-field digital mammography more accurate than screen-film mammography in overall population screening? A systematic review and meta-analysis. , 2013, Breast.

[2]  A. Jemal,et al.  Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. , 2012, The Lancet. Oncology.

[3]  M. Greuter,et al.  Safety and cost‐effectiveness of shortening hospital follow‐up after breast cancer treatment , 2012, The British journal of surgery.

[4]  R. Legood,et al.  Cervical cancer screening among HIV‐infected women: An economic evaluation in a middle‐income country , 2012, International journal of cancer.

[5]  S. Duffy,et al.  S4-1: Overdiagnosis in Breast Cancer Screening: Methodological Considerations of Current Estimates. , 2011 .

[6]  C. Lehman,et al.  Comparative Effectiveness of Digital Versus Film-Screen Mammography in Community Practice in the United States , 2011, Annals of Internal Medicine.

[7]  K. Sekiguchi,et al.  Management of locoregional recurrence of breast cancer , 2011, Breast cancer.

[8]  Jong-Hyeon Jeong,et al.  Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Mook,et al.  Independent prognostic value of screen detection in invasive breast cancer. , 2011, Journal of the National Cancer Institute.

[10]  T. Julian,et al.  Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. , 2011, Journal of the National Cancer Institute.

[11]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  N. Karssemeijer,et al.  Consequences of digital mammography in population-based breast cancer screening: initial changes and long-term impact on referral rates , 2010, European Radiology.

[13]  Ailton Augustinho Marchi,et al.  [Adherence to the opportunistic mammography screening in public and private health systems]. , 2010, Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia.

[14]  Ailton Augustinho Marchi,et al.  Adesão ao rastreamento mamográfico oportunístico em serviços de saúde públicos e privados , 2010 .

[15]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[16]  J. Cuzick,et al.  Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Thomas J. Smith,et al.  American Society of Clinical Oncology guidance statement: the cost of cancer care. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Schopper,et al.  How effective are breast cancer screening programmes by mammography? Review of the current evidence. , 2009, European journal of cancer.

[19]  G Scott Gazelle,et al.  Calibration of disease simulation model using an engineering approach. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  R. Freitas-Junior,et al.  [Temporal evolution of breast cancer stages in a population-based cancer registry in the Brazilian central region]. , 2009, Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia.

[21]  L. Tabár,et al.  Thirty years of experience with mammography screening: a new approach to the diagnosis and treatment of breast cancer , 2008, Breast Cancer Research.

[22]  Harry J de Koning,et al.  Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. , 2008, Journal of the National Cancer Institute.

[23]  Andrew H Briggs,et al.  Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  S. Goldie,et al.  Mathematical models of cervical cancer prevention in the Asia Pacific region. , 2008, Vaccine.

[25]  Klemen Rojnik,et al.  Probabilistic cost-effectiveness modeling of different breast cancer screening policies in Slovenia. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[27]  Jean B. Cormack,et al.  Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. , 2008, Radiology.

[28]  B. Hillner,et al.  Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer , 2007 .

[29]  P. Skaane,et al.  Randomized trial of screen-film versus full-field digital mammography with soft-copy reading in population-based screening program: follow-up and final results of Oslo II study. , 2007, Radiology.

[30]  Jeremy D Goldhaber-Fiebert,et al.  Cost-effectiveness of HPV 16, 18 vaccination in Brazil. , 2007, Vaccine.

[31]  Michael Waller,et al.  Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial , 2006, The Lancet.

[32]  J. Ioannidis,et al.  Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. , 2006, Journal of the National Cancer Institute.

[33]  C. Geyer,et al.  Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  H. Møller,et al.  Over-diagnosis in breast cancer screening , 2006, BMJ : British Medical Journal.

[35]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer. , 2006, The New England journal of medicine.

[36]  Emily White,et al.  Factors contributing to mammography failure in women aged 40-49 years. , 2004, Journal of the National Cancer Institute.

[37]  T. Tuttle,et al.  Trends in the treatment of ductal carcinoma in situ of the breast. , 2004, Journal of the National Cancer Institute.

[38]  C. Boni,et al.  Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Sabourin,et al.  Evaluation rétrospective du coût du cancer du sein dans un Centre de lutte contre le cancer , 2002 .

[40]  C. Boni,et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  K. Kerlikowske,et al.  Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. , 2000, Archives of internal medicine.

[42]  N. Devlin,et al.  The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand. , 1996, Health policy.

[43]  L. Solin,et al.  Cost of breast cancer treatment. A 4-year longitudinal study. , 1996, Archives of internal medicine.

[44]  D. Barry,et al.  An Ethnohistory of a Granny Midwife , 1996 .

[45]  B. Cady.  Cost-effective preoperative evaluation, operative treatment, and postoperative follow-up in the breast cancer patient. , 1996, The Surgical clinics of North America.

[46]  Y. Tao,et al.  Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  B. Hillner.  Economic and cost-effectiveness issues in breast cancer treatment. , 1996, Seminars in oncology.

[48]  C. J. Rosenquist,et al.  The cost-effectiveness of mammographic screening strategies. , 1995, JAMA.

[49]  C. Furnival,et al.  Estimating treatment cost functions for progressive diseases: a multiproduct approach with an application to breast cancer. , 1995, Journal of health economics.

[50]  J D Habbema,et al.  A model for breast cancer screening , 1990, Cancer.

[51]  Eto,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[52]  L. Arrighi,et al.  [Treatment of breast cancer]. , 1971, Prensa medica argentina.

[53]  A. Chagpar,et al.  Epidemiology of Ductal Carcinoma In Situ , 2015 .

[54]  F. H. Souza.  Mamografia digital em comparação com mamografia convencional no rastreamento de câncer de mama no Brasil : revisão sistemática, custo da doença e analise de custo-efetividade no Sistema Único de Saúde , 2012 .

[55]  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012 .

[56]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[57]  T. Stephens.  Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2011 .

[58]  Luciane Nascimento Cruz.  Medidas de qualidade de vida e utilidade em uma amostra da população de Porto Alegre , 2010 .

[59]  J. Thigpen.  Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen , 2010 .

[60]  Brasil. Ministério da Ciência,et al.  Diretrizes metodológicas: estudos de avaliação econômica de tecnologias em saúde , 2009 .

[61]  E. Pisano,et al.  Cost-effectiveness of digital mammography breast cancer screening. , 2008, Annals of internal medicine.

[62]  J. Peterse,et al.  Clinical Outcome after Selective Treatment of Patients Diagnosed with Ductal Carcinoma In Situ of the Breast , 2007, Annals of Surgical Oncology.

[63]  Mitchell D. Feldman,et al.  Full-field digital mammography compared with screen-film mammography in the detection of breast cancer: rays of light through DMIST or more fog? , 2007, Breast Cancer Research and Treatment.

[64]  J. Sabourin,et al.  [Cost of treatment and follow up of breast cancer: a retrospective assessment in a comprehensive cancer centre]. , 2002, Bulletin du cancer.

[65]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[66]  Marvin Zelen,et al.  Clinical Guidelines Annals of Internal Medicine Effects of Mammography Screening Under Different Screening , 2022 .